Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Clin Gastroenterol Hepatol. 2020 Oct 8;20(1):126–135. doi: 10.1016/j.cgh.2020.10.003

Figure 4.

Figure 4.

Comparative effectiveness of vedolizumab vs TNF antagonist therapy in UC for achieving steroid-free clinical remission and steroid-free deep remission. (A) Comparative effectiveness of vedolizumab vs TNF antagonist therapy for steroid-free clinical remission. (B) Comparative effectiveness of vedolizumab vs TNF antagonist therapy for steroid-free deep remission (steroid-free clinical + endoscopic remission). CI, confidence interval; IPW, inverse probability weighting; TNF antagonist, tumor necrosis factor antagonist (infliximab, adalimumab, golimumab); UC, ulcerative colitis. Analyses restricted to patients on steroids at baseline. Steroid-free deep remission was defined as achieving clinical remission, endoscopic remission, tapering off steroids, and no repeat steroid prescription for at least 4 weeks.